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Introduction on PET: Description
of Basics and Principles
Aren van Waarde
Abstract
Positron emission tomography (or PET) is a non-destructive imaging
technique in nuclear medicine with several unique properties: high sen-
sitivity, low radiation dose, possibility to correct data for attenuation
and scatter (thus quantitative), radioactive labeling of natural sub-
stances or drugs with high specific radioactivities so that these can be
used as tracers to monitor the pharmacokinetics of the non-radioactive
compounds. Limitations are the spatial resolution of commercially
available PET cameras, resulting in blurring or non-visibility of objects
smaller than 1 mm, and the short half-lives of the commonly used PET
radionuclides (< 2 h). Because of the combination of positron emitters,
specific radiopharmaceuticals and quantitative data analysis, PET is fre-
quently used to study the pharmacokinetics and pharmacodynamics of
test drugs non-invasively in humans.
Positron Emission Tomography or PET is a medical imaging technique
providing information on tissue biochemistry rather than anatomy
(Paans et al., 2000; Cherry, 2001; Levin, 2005; Wang et al., 2005).
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The term tomography indicates that two-dimensional images are
acquired of several adjacent cross-sections (“planes” or “slices”) within
the subject’s body (Fig. 1). The word emission shows that these images
are generated after intravenous injection of a radioactive compound
(the “radiopharmaceutical”) into the volunteer or the experimental
animal (Fig. 1). The radiopharmaceutical is transported throughout
the body by the circulation and taken up by target organs resulting
in the emission of externally detectable radiation. The emitted radia-
tion is measured by a PET camera and used for imaging. The
radiopharmaceuticals which are used in PET are marked with radionu-
clides which decay by the emission of positrons (Fig. 2). Positrons are
anti-electrons, i.e. particles with the same mass as an electron but a pos-
itive in stead of a negative charge. This form of radioactive decay is
important both for image reconstruction and for the interpretation of
PET images.
A PET camera does not detect the positrons themselves for their
range of travel within tissue is too short (less than 2.5 mm). Rather,
the camera detects the two gamma quanta which originate from the
annihilation of these anti-electrons. When a positron meets a normal
electron, the combined mass of the two particles is converted to
energy in a process that is called annihilation. Annihilation of a
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Fig. 1 Explanation of the term “positron emission tomograpy”.
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positron results in the formation of two 511 keV photons which are
emitted in anti-parallel (i.e. approximately 180 degrees opposite) direc-
tions (Fig. 2). These high-energy photons leave the body and are
counted by detectors in the PET camera. Electronic circuits connected
to the detector rings ensure that events are only registered when two
detectors are (virtually) simultaneously hit by a photon. This coinci-
dence detection has important advantages: (1) a low background count
rate and a good signal-to-noise ratio of the detector system; (2) no col-
limator (i.e. no lead shield with narrow holes) is required for position
information, resulting in a high sensitivity of PET cameras com-
pared to normal gamma cameras using single photon emitters; and
(3) images can be corrected for attenuation and scatter of the radiation
within tissue. This correction is accomplished by making a transmis-
sion scan of the subject (patient, volunteer or experimental animal),
using an external (68Ge/68Ga) gamma source, or by making a CT scan.
Emission images (acquired after injection of the radiopharmaceutical)
can then be corrected for attenuation measured with the external
source, on the condition that the subject does not move between
acquisition of the transmission (or CT) and emission scans. Thus, bio-
chemical and physiological processes can be measured quantitatively.
A fundamental limitation in the spatial resolution of PET 
images is the range of positrons within tissue (Levin et al., 1999;
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Fig. 2 Radioactive decay of 11C and positron annihilation.
(Illustration provided by Dr. J. Carney, Dept. Radiology, University of Pittsburgh.)
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Phelps et al., 1975; Tai et al., 2005). This varies from less than 1 mm
for 18F to 2.5 mm for 15O, at the mean positron energy which is 40%
of the maximum. Since the annihilation occurs at another location
than the positron decay, the range traveled by the positron makes it
impossible to estimate the decay position with absolute precision.
Since the elements carbon, nitrogen and oxygen have positron-
emitting isotopes (11C, 13N and 15O, respectively), drugs and bio-
molecules can be labeled with a positron emitter without changing
their chemical properties. These isotopes can also be prepared with
high specific radioactivities. Metabolites, neurotransmitters, hor-
mones and drugs can therefore be labeled with positron emitters and
be used as tracers to monitor the pharmacokinetics of the endoge-
nous substance (or the non-radioactive test drug). A high specific
radioactivity is particularly important in the case of receptor ligands,
enzyme inhibitors or transporter blockers binding to a limited
number of sites.
The radionuclides which are commonly used in PET have very
short half-lives (15O: two minutes, 13N: ten minutes, 11C: 20 minutes,
18F: 109.8 minutes, respectively). Transport of carbon-11, nitrogen-
13 and oxygen-15 over large distances is therefore impossible. Such
radionuclides should be produced locally. 11C, 13N, 15O and 18F are
made by nuclear reactions (Table 1). 11C, for example, is made by irra-
diating nitrogen gas with protons. Protons of the right energy evoke
the following nuclear reaction:
14N (p,α) 11C
The particles (protons or deuterons) causing the reaction are accel-
erated by means of a cyclotron. Small, dedicated medical cyclotrons are
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Table 1 Radionuclides for PET.
Theoretical specific
Nuclide Half-life (min) Decay product Nuclear reaction activity (Ci/mmol)
11C 20.4 11B 14N (p,α) 11C 9.22 × 106
13N 9.96 13C 16O (p,α) 13N 1.89 × 107
15O 2.1 15N 14N (d,n) 15O 9.08 × 107
18F 109.8 18O 18O (p,n) 18F 1.71 × 106
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commercially available. In combination with sophisticated targetry,
they can produce 11C, 13N, 15O and 18F in large amounts. In a cyclotron
target, only simple molecules are formed. When the nitrogen gas used
for production of 11C is mixed with a trace of oxygen, the end prod-
uct of the reaction is 11C-carbon dioxide. Such simple building blocks
(e.g. 11CO2, 11CO, 13NH4+, 13NO3−, 13NO2−) are used to synthesize the
desired radiopharmaceuticals (see Table 1).
Since the half-lives of positron-emitting radionuclides are short,
only rapid labeling procedures can be employed for radiopharmaceu-
tical production. Radiochemists are responsible for these production
processes. Many compounds are labeled by a single-step reaction of a
des-methyl precursor with 11C-methyl triflate or 11C-methyl iodide.
The final product then contains a 11C-labeled methoxy or N-methyl
group. Fluorine substitutions on an aromatic ring using 18F-fluoride
are also frequently employed for labeling. Synthesis modules for the
automated production of common radiopharmaceuticals (e.g. 18F-
FDG, 18F-FLT, 18F-DOPA, 13N-ammonia, 11C-acetate and labeled
substances produced by 11C-methylation) can be purchased from sev-
eral suppliers.
The short half-lives of positron emitters can be considered as a
disadvantage of PET, since a local cyclotron and facilities for radio-
pharmaceutical production are required and biological processes with
slow kinetics (e.g. the binding of antibodies to their targets) cannot
be examined. However, the rapid decay may also be considered as an
advantage. Relatively high doses of a positron emitter (several hun-
dreds of MBq) can be administered to a subject, allowing the
acquisition of images with good counting statistics for about three
half-lives. Because of the short half-life of the employed radioactivity,
the total radiation burden for the subject (i.e. the integral of radioac-
tivity over time) remains low. The radiation burden for an average
PET scan is 1 to 3 mSv, an order of magnitude lower than the aver-
age radiation burden for a CT scan (10 to 20 mSv). PET scans can
therefore be made in healthy volunteers and subjects can be scanned
repeatedly, e.g. at baseline and at two different time points after inges-
tion of a test drug (see Fig. 3).
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Each PET study requires the harmonious cooperation of
chemists, pharmacists, physicists and physicians. The scanning proto-
col proceeds in a number of logical steps: (1) production of
radioactivity; (2) preparation of the desired radiopharmaceutical; (3)
purification, sterilization and quality control; (4) administration of
the tracer to the experimental animal or the human subject; (5) data
acquisition; (6) image reconstruction; (7) analysis of the data with
tracer-kinetic models; and (8) reporting to the investigator or the
physician of the patient.
Many physiological and biochemical processes can be quantified
with a PET camera (see Table 2). These include: blood flow (tissue
perfusion), blood volume in a region of interest, glucose consump-
tion, amino acid transport, lipid metabolism (activity of choline
kinase), oxidative metabolism (Krebs cycle activity), the rate of syn-
thesis of various neurotransmitters (e.g. dopamine, serotonin), the
regional distribution and density of many receptors (e.g. binding sites
for dopamine, noradrenaline, serotonin, acetylcholine, bombesin,
neurokinin), biomarkers of cellular proliferation (e.g. EGF receptor
density, sigma receptor density, rate of incorporation of nucleosides
6 A. van Waarde
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Fig. 3 Example of a receptor occupancy study performed in our institution. Three scans
of the brain of a healthy volunteer were made, using the sigma-1 receptor ligand 11C-
SA4503: (a) at baseline (left image); (b) 3 h (middle image); and (c) 21 h (right image) after
oral administration of an unlabeled sigma-1 agonist. Receptor occupancy was high
(> 80%) after 3 h and showed only a minor decrease during the subsequent 21 h.
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Table 2 PET tracers available in our institution.
Radiopharmaceutical Process visualized Treated tissue/organ
15O-Water Blood flow Brain, heart
13N-Ammonia Blood flow Heart
15O-Carbon Monoxide Blood volume Brain, heart, lungs, tumors
18F-Fluorodeoxyglucose Glucose consumption Brain, heart, tumors, muscle
11C-Methionine Amino acid transport Tumors
1-11C-Tyrosine Amino acid transport Brain, tumors
11C-Choline Choline kinase activity Tumors
11C-Acetate Oxidative metabolism Heart
18F-Fluoro-L-DOPA Dopamine synthesis rate Brain, neuroendocrine tumors
11C-5-Hydroxytryptophan Serotonin synthesis rate Brain, neuroendocrine tumors
11C-Raclopride Dopamine D2/D3 receptors Brain (striatum)
11C-N-propyl- D2/D3 receptor 
norapomorphine (high affinity state) Brain (striatum)
11C-CGP12388 Beta-adrenoceptors Heart, lungs, spleen
18F-Fluorocarazolol Beta-adrenoceptors Heart, lungs, brain (animals)
18F-MPPF 5-HT1A receptors Brain
11C-VC002 Muscarinic cholinoceptors Heart, lungs
11C-VC003 Muscarinic cholinoceptors Brain
11C-SA4503 Sigma-1 receptors Brain, tumors
18F-FE-SA5845 Sigma-1/2 receptors Brain, tumors
11C-SA5845 Sigma-1/2 receptors Brain, tumors
11C-PK11195 Translocator protein Brain (activated microglia)
11C-DPA713 Translocator protein Brain (activated microglia)
18F-Bombesin Bombesin receptors Tumors (prostate)
18F-FES Estrogen receptors Tumors (breast)
18F-Substance P Neurokinin-1 receptors Lungs, tumors
18F-FAZA Hypoxia Tumors
11C-Meta-hydroxy- Noradrenalin 
ephedrine transporter activity Heart
18F-FLT Thymidine kinase-1 activity Tumors
18F-FHPG Viral thymidine kinase Brain, tumors (gene therapy)
18F-FHBG Viral thymidine kinase Brain, tumors (gene therapy)
18F-FEAU Viral thymidine kinase Brain, tumors (gene therapy)
11C-MP4A Acetylcholinesterase activity Brain
11C-Verapamil P-glycoprotein function Brain, tumors
11C-Carvedilol P-glycoprotein function Brain, tumors
11C-GR218231 P-glycoprotein function Brain, tumors
11C-PIB Beta-Amyloid plaques Brain
(Continued )
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into cellular DNA), biomarkers of inflammation (e.g. translocator
protein density, binding sites for interleukin-2), the expression levels
and activity of various transporters (e.g. P-glycoprotein, noradrenalin
transport, iodine transport), and the activity of important enzymes
(e.g. thymidine kinase, cyclooxygenase-2). Using specific radiophar-
maceuticals, PET can be applied in various ways during the drug
discovery process.
First, PET has important applications in pharmacodynamics.
Pharmacodynamics is the study of the effects of drugs in the healthy
and diseased body, including the mechanism of action and the rela-
tionship between drug concentration and effect. PET is capable of
measuring the metabolic response of tissues in the human body
quantitatively, repeatedly and noninvasively which can speed up
drug development and can significantly reduce the associated costs.
In oncology, PET may be employed to assess the effectiveness of
novel anti-cancer agents and to optimize therapeutic protocols, e.g.
by measuring the effect of the drug on glucose consumption, amino
acid uptake or nucleoside metabolism within tumor cells (Avril et
al., 2007; Kumar et al., 2007; Aboagye et al., 2003; Boss et al.,
2008). During the development of CNS drugs, PET is often used
to measure the dose-dependent occupancy of target receptors
within the human brain by a non-radioactive test compound 
(van Waarde, 2000; Passchier et al., 2002; Wong et al., 2009;
Talbot et al., 2002; Halldin et al., 2001)(see Fig. 3). Employing the
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Table 2 (Continued)
Radiopharmaceutical Process visualized Treated tissue/organ
18F-Desbromo-DuP697 Cyclooxygenase-2 expression Brain, tumors
11C-VIOXX Cyclooxygenase-2 expression Brain, tumors
124I-Iodide Thyroid imaging Thyroid
18F-Interleukin-2 Insulitis Pancreas
89Zr-Bevacizumab VEGF levels Tumor
89Zr-Cetuximab Epidermal growth Tumor
factor receptor
89Zr-Trastuzumab HER2/neu expression Tumor
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radioligand/unlabeled competitor approach, such studies can
answer the following questions:
(1) Does the unlabeled drug reach its intended target?
(2) How is occupancy of the target protein related to the adminis-
tered dose?
(3) What is the relationship between target occupancy and plasma
kinetics of the drug?
(4) Which level of receptor occupancy is required for the beneficial
effect?
(5) At which threshold level of occupancy do unwanted side effects
arise?
(6) What is the optimal dose regime (beneficial effect reached but
side effects largely avoided)?
(7) Is occupancy of the target in non-responders lower than in
responders, or do other factors preclude the beneficial effect?
By studying only a limited number of volunteers, these questions
can be answered and the optimal dose regimen for further clinical
studies can be selected.
Second, if the test drug itself can be labeled with a positron emit-
ter, PET may be employed to study the pharmacokinetics of a novel
drug candidate. After intravenous injection, inhalation or ingestion of
the labeled compound, the time-dependent concentration of radioac-
tivity in different organs and tissues can be measured quantitatively
(Klimas, 2002; Hutchinson et al., 2003; Fischman et al., 2000;
Berridge et al., 2000) (see Fig. 4). Since the drug is labeled with a
high specific radioactivity, only minute doses of the test compound
need to be administered for accurate measurements with a PET cam-
era. This “microdosing” approach facilitates PET studies in human
subjects at an early stage of drug development (Bauer et al., 2008;
Wagner et al., 2008). The role of the blood-brain barrier in drug
delivery to the brain can be assessed, e.g. by measuring brain uptake
of the test compound in the presence and absence of a modulator 
of P-glycoprotein (Elsinga et al., 2004). Various strategies 
for drug delivery can be compared, e.g. various liposome formula-
tions (Oku et al., 2000). The effect of specific interventions on
Introduction on PET: Description of Basics and Principles 9
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pharmacokinetic parameters can also be examined, e.g. the impact of
inhibition of the plasma protein binding (Haradahira et al., 2000),
metabolic degradation (Tipre et al., 2006; Doudet et al., 1997) or
excretion (Lu et al., 2000) of the test substance.
A relatively novel concept regarding the role of PET in drug dis-
covery is the contribution of this imaging technique to ‘personalized
medicine’ (Eckelman et al., 2008; Pither, 2003; Smith, 2005). Novel
targeted anticancer drugs are often highly effective in a small sub-
population of patients, but the overall response rate is low. In order
for these drugs to be effective, the target must be present during
treatment. Radiolabeled peptides (or antibody fragments) and nuclear
imaging techniques like PET can be applied to examine whether the
target is expressed in the primary tumor or it metastases throughout
the patient’s body (Dijkers et al., 2008; Van de Wiele et al., 2008).
PET scans are more informative than biopsy samples, since there is no
risk of sampling errors and inaccessible (or unknown) lesions can be
visualized. By providing proof of the presence of the target, PET can
assist in the selection of the proper therapy for the individual patient.
10 A. van Waarde
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Fig. 4 Example of a PET study of drug pharmacokinetics. We labeled a tumor-targeting
antibody with the positron emitter 89Zr (half-life 3.27 d) and injected it into a tumor-
bearing mouse. Whole-body microPET scans were made of this animal at 24 h, 72 h and
168 h after injection. The contrast between the tumor (implanted into the right hindleg)
and non-target organs showed a steady increase during the 168 h period.
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The risk of application of costly therapies to non-responders (result-
ing in a dangerous loss of time and unwanted side effects) may be
reduced and the success rate for the individual patient increased.
Because of the combination of positron-emitting radionuclides,
specific radiopharmaceuticals and quantitative data analysis, PET
offers unique possibilities to study drug pharmacokinetics and phar-
macodynamics non-invasively in humans. Increasing cooperation
between nuclear medicine specialists, basic scientists, and pharmaceu-
tical companies will definitely lead to many future applications of PET
in the drug discovery process.
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